Immunomodulatory Effect after Irreversible Electroporation in Patients with Locally Advanced Pancreatic Cancer

Table 1

Characteristics of patients with LAPC undergoing IRE therapy.

Characteristics		Number	Percentage (%)
Patients		34	100
Age (years)	≤ 60	19	55.9
	> 60	15	44.1
Gender	Female	18	52.9
	Male	16	47.1
Tumor size (cm)	≤ 2	1	2.9
	2~4	19	55.9
	>4	14	41.2
Tumor grade	Well	2	5.9
	Moderate	19	55.9
	Poor	13	38.2
Tumor site	Head	17	50.0
	Body / Tail	17	50.0
WBC (109)	≤ 10	30	88.2
	> 10	4	11.8
HGB (g/L)	≤ 120	10	29.4
	> 120	24	70.6
PLT (109)	≤ 300	29	85.3
	> 300	5	14.7
ALT (U/L)	≤ 40	25	73.5
	> 40	9	26.5
AST (U/L)	≤ 40	28	82.4
	> 40	6	17.6
ALP (U/L)	≤ 100	18	52.9
	> 100	16	47.1
GGT (U/L)	≤ 45	18	52.9
	> 45	16	47.1
ALB (g/L)	≤ 40	3	8.8
	> 40	31	91.2
TBIL (umol/L)	≤ 20.5	26	76.5
	> 20.5	8	23.5
IBIL (umol/L)	≤ 15	30	88.2
	> 15	4	11.8
CRP (ng/L)	≤ 3	25	73.5
	> 3	9	26.5
CEA (ng/mL)	≤ 5	20	58.8
	> 5	14	41.2
CA19-9 (U/ml)	≤ 35	8	23.5
	> 35	26	76.5
NLR	≤ 1.47	9	26.5
	> 1.47	25	73.5
PLR	≤ 165.29	22	64.7
	> 165.29	12	35.3
PI	0	25	73.5
	1	9	26.5
mGPS	0	29	85.3
	1	4	11.8
	2	1	2.9

LAPC, locally advanced pancreatic cancer; IRE, irreversible electroporation; WBC, white blood cell count; PLT, platelet count; ALT, alanine transaminase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, glutamyl transpeptidase; ALB, albumin; TBIL, total bilirubin; IBIL, indirect bilirubin; CRP, C-reactive protein; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; PI, prognostic index; mGPS, modified Glasgow Prognostic Score.